These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11997871)

  • 21. Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer.
    Gresner P; Gromadzinska J; Wasowicz W
    Lung Cancer; 2007 Jul; 57(1):1-25. PubMed ID: 17337085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetic phenotyping and genotyping. Present status and future potential.
    Gonzalez FJ; Idle JR
    Clin Pharmacokinet; 1994 Jan; 26(1):59-70. PubMed ID: 8137598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping].
    Goldenkova-Pavlova IV; Bruskin SA; Abdeev RM; Markarova EV; Bigvava SG; Radkevich LA; Kozhekbaeva ZhM; Glotov AS; Gra OA; Zasedatelev AS; Nasedkina TV; Kurdanov KhA; Piruzian ES
    Genetika; 2006 Aug; 42(8):1143-50. PubMed ID: 17025166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
    Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
    Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The biochemistry of drug metabolism--an introduction: part 6. Inter-individual factors affecting drug metabolism.
    Krämer SD; Testa B
    Chem Biodivers; 2008 Dec; 5(12):2465-578. PubMed ID: 19089818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism.
    Winter HR; Unadkat JD
    Drug Metab Dispos; 2005 Jul; 33(7):969-76. PubMed ID: 15843491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Xenobiotic gene polymorphisms and susceptibility to multiple myeloma.
    Lincz LF; Kerridge I; Scorgie FE; Bailey M; Enno A; Spencer A
    Haematologica; 2004 May; 89(5):628-9. PubMed ID: 15136237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.
    Suh JW; Koo BK; Zhang SY; Park KW; Cho JY; Jang IJ; Lee DS; Sohn DW; Lee MM; Kim HS
    CMAJ; 2006 Jun; 174(12):1715-22. PubMed ID: 16754899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic regulation of warfarin metabolism and response.
    Daly AK; Aithal GP
    Semin Vasc Med; 2003 Aug; 3(3):231-8. PubMed ID: 15199455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.
    Lötsch J; Skarke C; Wieting J; Oertel BG; Schmidt H; Brockmöller J; Geisslinger G
    Clin Pharmacol Ther; 2006 Jan; 79(1):72-89. PubMed ID: 16413243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.
    Mathijssen RH; van Schaik RH
    Eur J Cancer; 2006 Jan; 42(2):141-8. PubMed ID: 16325399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic factors in drug metabolism.
    Belle DJ; Singh H
    Am Fam Physician; 2008 Jun; 77(11):1553-60. PubMed ID: 18581835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Individualized pharmacotherapy based on cytochrome P-450 (CYP) genotyping].
    Johansen PW; Bergan S; Rootwelt H; Kvittingen EA; Rugstad HE
    Tidsskr Nor Laegeforen; 2002 Nov; 122(29):2781-3. PubMed ID: 12523145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacogenetics in pediatrics].
    Aigrain EJ
    Arch Pediatr; 2000 May; 7 Suppl 2():365s-367s. PubMed ID: 10904775
    [No Abstract]   [Full Text] [Related]  

  • 35. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.
    Sugamori KS; Wong S; Gaedigk A; Yu V; Abramovici H; Rozmahel R; Grant DM
    Mol Pharmacol; 2003 Jul; 64(1):170-9. PubMed ID: 12815173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of genetic factors and illnesses on drug efficacy].
    Feuring M; Wehling M; Falkenstein E
    Internist (Berl); 2000 Apr; 41(4):332-7. PubMed ID: 10798180
    [No Abstract]   [Full Text] [Related]  

  • 38. Overall evaluation and research perspectives.
    Vineis P; d'Errico A; Malats N; Boffetta P
    IARC Sci Publ; 1999; (148):403-8. PubMed ID: 10493267
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug-drug interactions and the cytochrome P450 system: an update.
    Shannon M
    Pediatr Emerg Care; 1997 Oct; 13(5):350-3. PubMed ID: 9368253
    [No Abstract]   [Full Text] [Related]  

  • 40. [Characteristics and design of the studies evaluating pharmacological interactions].
    Montané E; López A; Costa J
    Med Clin (Barc); 2013 Jul; 141(2):82-6. PubMed ID: 23706685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.